Synonym
lanabecestat; AZD3293; AZD-3293; AZD 3293; LY3314814; LY-3314814; LY 3314814.
IUPAC/Chemical Name
(1r,4r)-4-methoxy-5''-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine
InChi Key
WKDNQONLGXOZRG-HDVKRFLQSA-N
InChi Code
InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)/t22-,25-,26?
SMILES Code
NC(C(C)=N1)=NC21C3=C(C=CC(C4=CC(C#CC)=CN=C4)=C3)C[C@@]52CC[C@@H](OC)CC5
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
412.54
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Eketjäll S, Janson J, Kaspersson K, Bogstedt A, Jeppsson F, Fälting J,
Haeberlein SB, Kugler AR, Alexander RC, Cebers G. AZD3293: A Novel, Orally Active
BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate
Kinetics. J Alzheimers Dis. 2016;50(4):1109-23. doi: 10.3233/JAD-150834. PubMed
PMID: 26890753; PubMed Central PMCID: PMC4927864.
2: Cebers G, Alexander RC, Haeberlein SB, Han D, Goldwater R, Ereshefsky L,
Olsson T, Ye N, Rosen L, Russell M, Maltby J, Eketjäll S, Kugler AR. AZD3293:
Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients
with Alzheimer's Disease. J Alzheimers Dis. 2017;55(3):1039-1053. PubMed PMID:
27767991.
3: Ghosh AK, Tang J. Prospects of β-Secretase Inhibitors for the Treatment of
Alzheimer's Disease. ChemMedChem. 2015 Sep;10(9):1463-6. doi:
10.1002/cmdc.201500216. PubMed PMID: 26140607.
